| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
As a stable isotope-labeled compound, L-Aspartic acid-d3 does not exert pharmacological effects through traditional target binding. Instead, its "targets" are the metabolic pathways in which L-aspartic acid participates. L-Aspartic acid is an amino acid that serves as a precursor molecule for active compound delivery specifically targeting the colon. It can penetrate the blood-brain barrier, allowing it to interact with central nervous system metabolic pathways. L-Aspartic acid is commonly used in the study of inflammatory conditions, suggesting it may interact with inflammatory signaling pathways. As an amino acid, it is involved in protein synthesis, neurotransmission, and the urea cycle. The deuterium label allows researchers to track the metabolic fate of L-aspartic acid in various biological systems using mass spectrometry. The compound's ability to serve as a prodrug component for colon-targeted delivery indicates that it may be recognized by transporters or enzymes in the gastrointestinal tract. Its role as an endogenous metabolite makes it a useful tool for studying amino acid metabolism and inflammatory conditions.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro, L-Aspartic acid-d3 is used as an internal standard and tracer in mass spectrometry and metabolic studies. The compound is added to biological samples (e.g., plasma, urine, cell lysates) at known concentrations prior to sample preparation to correct for matrix effects, extraction efficiency, and instrument variability. The deuterium labeling ensures that the compound can be distinguished from endogenous L-aspartic acid in mass spectrometry-based assays, allowing for accurate quantification even in complex biological matrices. In metabolic studies, L-Aspartic acid-d3 is added to cell culture media to study aspartic acid uptake, metabolism, and incorporation into proteins. Cells are cultured in standard growth media, and L-Aspartic acid-d3 is added at various concentrations for varying periods. Following incubation, cells are harvested, and intracellular metabolites are extracted. The extracts are then analyzed by LC-MS/MS to measure the deuterium enrichment of aspartic acid and its metabolites. This allows researchers to quantify aspartic acid metabolism and its role in various cellular processes. |
| ln Vivo |
In vivo, L-Aspartic acid-d3 enables precise tracking of aspartic acid metabolism in complex biological systems. The unlabeled compound, L-aspartic acid, can penetrate the blood-brain barrier and is commonly used for preparing prodrugs to target colon and cecal tissues. Following administration to animals (typically via oral gavage, intraperitoneal injection, or intravenous infusion), the compound is distributed throughout the body and incorporated into various metabolic pathways. The deuterium label allows for the specific detection of administered L-aspartic acid in biological samples without interference from endogenous unlabeled L-aspartic acid. Blood and tissue samples are collected at various time points, and the deuterium enrichment of aspartic acid and its metabolites is measured by mass spectrometry. This allows researchers to quantify aspartic acid metabolism in different organs and tissues, assess the impact of disease states on aspartic acid homeostasis, and evaluate the effects of pharmacological interventions. The compound's ability to penetrate the blood-brain barrier makes it particularly useful for studying central nervous system metabolism.
|
| Enzyme Assay |
In vitro enzyme and receptor binding assays are not typically performed with L-Aspartic acid-d3, as it is primarily used as an analytical standard and tracer. However, the compound can be used as a labeled substrate in enzymatic assays to study the activity of enzymes involved in aspartic acid metabolism. For example, in assays of aspartate aminotransferase (AST), the enzyme is incubated with L-Aspartic acid-d3 and α-ketoglutarate, and the formation of labeled oxaloacetate and glutamate is measured by mass spectrometry. In assays of asparagine synthetase, L-Aspartic acid-d3 can be used as a substrate to study the conversion of aspartic acid to asparagine. The use of a labeled substrate allows for the specific detection of enzyme-derived products without interference from endogenous unlabeled metabolites. These assays are typically performed in buffered solutions at physiological pH and temperature, with reaction termination by addition of acid or organic solvent. The compound's high purity and isotopic enrichment ensure accurate and reproducible results in these biochemical assays.
|
| Cell Assay |
In vitro cell-based experiments with L-Aspartic acid-d3 involve adding the labeled compound to cell culture media and studying its uptake and metabolism. Cells are cultured in standard growth media, and L-Aspartic acid-d3 is added at various concentrations (typically 0.1-10 mM) for varying periods (minutes to hours). Following incubation, cells are harvested, and intracellular metabolites are extracted using organic solvents or perchloric acid. The extracts are then analyzed by LC-MS/MS to measure the deuterium enrichment of aspartic acid and its metabolites. This allows researchers to quantify aspartic acid uptake, incorporation into proteins, and conversion to other metabolites such as asparagine, oxaloacetate, and fumarate. In metabolic flux analysis experiments, cells are cultured in media containing L-Aspartic acid-d3 for several hours or days, and the labeling pattern of metabolites is analyzed to calculate metabolic fluxes. The compound is also used in pulse-chase experiments, where cells are briefly exposed to L-Aspartic acid-d3 (pulse) and then switched to unlabeled media (chase) to study the turnover of aspartic acid-containing molecules. Cell viability is routinely monitored to ensure that the labeled compound does not affect cell health.
|
| Animal Protocol |
In vivo animal experiments with L-Aspartic acid-d3 involve administration of the labeled compound to animals followed by collection of blood and tissue samples for mass spectrometry analysis. The compound is typically administered via oral gavage, intraperitoneal injection, or intravenous infusion at doses ranging from 10-100 mg/kg. Following administration, blood samples are collected at various time points (typically 0, 15, 30, 60, 120, 240 minutes) to measure the appearance and disappearance of labeled aspartic acid in the circulation. At the end of the experiment, animals are euthanized, and tissues (liver, kidney, brain, muscle) are collected for analysis. Metabolites are extracted from plasma and tissues, and the deuterium enrichment of aspartic acid and its metabolites is measured by LC-MS/MS. This allows researchers to quantify aspartic acid metabolism in different organs and tissues, assess the impact of disease states on aspartic acid homeostasis, and evaluate the effects of pharmacological interventions. All animal procedures are conducted in accordance with institutional animal care and use committee guidelines, with appropriate sample sizes (typically n=4-6 per group) to ensure statistical power.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of L-Aspartic acid-d3 are studied using the isotope label to track the absorption, distribution, metabolism, and excretion of L-aspartic acid. Following oral or intravenous administration, the compound is rapidly absorbed and distributed to tissues. The deuterium label allows for the specific detection of administered L-aspartic acid in biological samples without interference from endogenous unlabeled L-aspartic acid. Pharmacokinetic parameters such as half-life, volume of distribution, clearance, and bioavailability can be calculated from the concentration-time profiles of labeled aspartic acid in plasma and tissues. L-Aspartic acid is a non-essential amino acid that is synthesized in the body and is involved in various metabolic pathways. It is transported across cell membranes by amino acid transporters and is metabolized through several pathways, including transamination to oxaloacetate, decarboxylation to β-alanine, and incorporation into proteins. The labeled compound enables precise tracking of these metabolic processes. The pharmacokinetics of L-Aspartic acid-d3 are expected to be similar to those of unlabeled L-aspartic acid, with rapid distribution and elimination.
|
| Toxicity/Toxicokinetics |
The toxicological profile of L-Aspartic acid-d3 is consistent with that of natural L-aspartic acid, a non-essential amino acid that is synthesized in the body and is generally recognized as safe at physiological concentrations. L-Aspartic acid is a normal component of the diet and is involved in various metabolic pathways. The deuterium label is a stable isotope that does not impart any additional toxicity to the compound. The compound is supplied as a high-purity research chemical for laboratory use only and is not intended for human consumption. Standard safety precautions should be observed when handling the compound, including the use of appropriate personal protective equipment. The compound should be stored at -20°C in a dry place, away from light and moisture. As with all chemicals, ingestion, inhalation, and skin contact should be avoided. The compound's safety profile is supported by the extensive use of stable isotope-labeled amino acids in research and clinical diagnostics. There are no known adverse effects associated with the use of L-Aspartic acid-d3 at the concentrations typically used in research applications.
|
| References | |
| Additional Infomation |
L-Aspartic acid-d3 is a valuable research tool for metabolic studies, mass spectrometry, and drug delivery research. It is the deuterium-labeled form of the endogenous amino acid L-aspartic acid. L-Aspartic acid is an amino acid that can penetrate the blood-brain barrier and is commonly used for preparing prodrugs to target colon and cecal tissues. L-Aspartic acid is commonly used in the study of inflammatory conditions. The compound has the molecular formula C₄H₄D₃NO₄ and a molecular weight of 136.12 g/mol. It is supplied as a high-purity research chemical (≥95% purity) and is soluble in water (≥9.26 mg/mL). L-Aspartic acid-d3 is used as an internal standard and tracer for the quantification of L-aspartic acid in biological samples by LC-MS/MS. The compound is not a drug and is not approved for any clinical indication. It is strictly for research use only. Its role as a stable isotope-labeled amino acid makes it an essential tool for studying amino acid metabolism, neurotransmitter synthesis, and drug delivery systems.
|
| Molecular Formula |
C4H4D3NO4
|
|---|---|
| Molecular Weight |
136.12
|
| Exact Mass |
136.056
|
| CAS # |
3842-25-9
|
| Related CAS # |
L-Aspartic acid;56-84-8
|
| PubChem CID |
12308669
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
264.1±30.0 °C at 760 mmHg
|
| Melting Point |
>300ºC (dec.)(lit.)
|
| Flash Point |
113.5±24.6 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.531
|
| LogP |
-0.67
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
9
|
| Complexity |
133
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
[2H][C@@](C(=O)O)(C([2H])([2H])C(=O)O)N
|
| InChi Key |
CKLJMWTZIZZHCS-RBXBQAPRSA-N
|
| InChi Code |
InChI=1S/C4H7NO4/c5-2(4(8)9)1-3(6)7/h2H,1,5H2,(H,6,7)(H,8,9)/t2-/m0/s1/i1D2,2D
|
| Chemical Name |
(2S)-2-amino-2,3,3-trideuteriobutanedioic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: ≥ 9.26 mg/mL (68.03 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.3465 mL | 36.7323 mL | 73.4646 mL | |
| 5 mM | 1.4693 mL | 7.3465 mL | 14.6929 mL | |
| 10 mM | 0.7346 mL | 3.6732 mL | 7.3465 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
